A clinical study on the efficacy and safety of the exopolymers from Aureobasidium pullulans (EAP) in subjects with mild-to-moderate atopic dermatitis

Park, Hye-Su; Kang, Min-Seo; Kim, Yongmin; Lim, Jong‐Min; Kim, Young Suk; Kim, Hee-Taek; Choi, Jae‐Suk

doi:10.1007/s13530-020-00040-y

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exopolymers purified from Aureobasidium pullulans SM-2001 (EAP; its solubility is about 10% in water), the test food material used in this study, containing 13% -1,3/1,6-glucan [23], are used in foods and have shown potent immunomodulatory activities in a mouse model [16]. In addition, EAP showed no adverse events in clinical studies designed to evaluate its effectiveness on bone metabolism improvement [24,25] and on atopic dermatitis [26]. Therefore, -glucan is considered safe for human ingestion.…”

Section: Introductionmentioning

confidence: 99%

Ingestion of Exopolymers from Aureobasidium pullulans Reduces the Duration of Cold and Flu Symptoms: A Randomized, Placebo‐Controlled Intervention Study

Lim¹,

Park³

et al. 2018

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Aim The objective of the study was to assess the efficacy of exopolymers from Aureobasidium pullulans (EAP) on the incidence of colds and flu in healthy adults. Methods We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30–70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and flu symptoms, a primary variable in assessing effectiveness, and serum cytokine levels as well as WBC counts as secondary variables were also evaluated. Results EAP was associated with a statistically significant decrease in the duration of cold and flu symptoms, a primary variable in assessing effectiveness. Although cold and flu symptom levels were not significantly different at a significance level of 5%, the cold and flu symptom levels of the EAP group were less severe compared to the placebo group. No statistically significant changes of serum cytokine levels as well as WBC counts were observed. Conclusion The results showed that EAP is a useful pharmaceutical and functional food material for preventing and treating colds and flu.

show abstract